X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CPI-818 (soquelitinib) is an investigational small molecule drug given orally designed to selectively inhibit ITK, which is being evaluated in the clinical trials for the treatment of atopic dermatitis.
Lead Product(s): Soquelitinib
Therapeutic Area: Dermatology Product Name: CPI-818
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 09, 2024
Details:
CPI-818 (soquelitinib) is the company’s lead ITK inhibitor small molecule drug candidate. It is being evaluated in phase 2 clinical trials for the treatment of relapsed peripheral T cell lymphoma.
Lead Product(s): Soquelitinib
Therapeutic Area: Oncology Product Name: CPI-818
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 08, 2024
Details:
CPI-818 (soquelitinib) is an investigational, oral, small molecule drug that selectively inhibited ITK in preclinical studies and is in a multicenter Phase 1/1b clinical trial in patients with several types of T cell lymphomas.
Lead Product(s): Soquelitinib
Therapeutic Area: Oncology Product Name: CPI-818
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2023
Details:
CPI-818 is an investigational, oral, small molecule drug that selectively inhibited ITK in preclinical studies and is in a multicenter Phase 1/1b clinical trial in patients with several types of T cell lymphomas.
Lead Product(s): Soquelitinib
Therapeutic Area: Oncology Product Name: CPI-818
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2023
Details:
CPI-818 is an investigational small molecule drug given orally that has selectively inhibited ITK (interleukin-2-inducible T cell kinase) in preclinical studies. It was designed to block malignant T cell growth and to modulate immune responses.
Lead Product(s): Soquelitinib
Therapeutic Area: Infections and Infectious Diseases Product Name: CPI-818
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2023
Details:
CPI-818 is an investigational small molecule drug given orally that has selectively inhibited ITK (interleukin-2-inducible T-cell kinase) in preclinical studies. It was designed to block malignant T-cell growth and to modulate immune responses.
Lead Product(s): Soquelitinib
Therapeutic Area: Oncology Product Name: CPI-818
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2022
Details:
CPI-444 (ciforadenant) is an investigational small molecule, oral, checkpoint inhibitor designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of adenosine in the tumor microenvironment to the A2A receptor.
Lead Product(s): Ciforadenant,Ipilimumab,Nivolumab
Therapeutic Area: Oncology Product Name: CPI-444
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2022
Details:
Mupadolimab (CPI-006) is a humanized monoclonal antibody designed to be directed against CD73 with a proposed unique mechanism of activating B cells to generate immune responses to tumor antigens and viruses, in patients with relapsed refractory NSCLC and HNSCC.
Lead Product(s): Mupadolimab,Pembrolizumab
Therapeutic Area: Oncology Product Name: CPI-006
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Angel Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2022
Details:
CPI-818 is an investigational, orally bioavailable, covalent inhibitor of ITK designed to have low nanomolar affinity. In vitro studies have shown that it potently inhibited T cell receptor signal transduction.
Lead Product(s): Soquelitinib
Therapeutic Area: Oncology Product Name: CPI-818
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2021
Details:
Mupadolimab (formerly CPI-006) is a humanized anti-CD73 antibody that binds to various immune cells including most B cells.
Lead Product(s): Mupadolimab
Therapeutic Area: Infections and Infectious Diseases Product Name: CPI-006
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 15, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
